The National Cancer Institute awarded a $317,420 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Calla Health Foundation, a for-profit, woman-owned small business, for the development and validation of a patient-ready device called the CallaScope. This innovative technology aims to transform provider-controlled speculum-based imaging in a clinic to a patient-controlled self-imaging procedure at home, enabling increased access to cervical cancer screening, diagnosis,...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The grant aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMIC). The key goals of the project are to: 1) Modify the IRISTM...
The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
This Cooperative Agreement award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $957,152 to GE Medical Systems Information Technologies, Inc. to develop and deploy an affordable automated point-of-care (POC) telecytology platform for oral cancer screening in India. The platform aims to reliably establish oral cancer diagnosis in community settings and enable immediate referral for treatment. Key project goals include creating a...
This Project Grant award, totaling $623,622, was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286). The goal is to develop a novel Probe-based Light Sheet Microscopy (PLSM) device and evaluate its clinical utility for in vivo imaging to aid anal cancer screening. The project, which runs from January 2025 to December 2028, involves a...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), will support the development and clinical validation of an Optical Coherence Tomography (OCT) system and two specialized OCT imaging probes to enhance colorectal cancer screening. The $1,471,777 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to create an OCT system that can obtain 3D microscopic images of...
Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...